Latest News and Press Releases

Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.

ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing...

Research Triangle Park, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG,...

Data demonstrating Quell’s ability to engineer Tregs to enhance their specific targeting and durability while maintaining their suppressive function and phenotypic stability to be presented in Oral...

Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT

coAAV-mediated gene transfer holds promise for expanding the scope of ocular diseases treatable via suprachoroidal administration Data to be presented in oral session at ASGCT 2024 Paris,...

SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today shared details of...

Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting Abstracts outline an approach which is highly translatable,...

Tome to present data at ASGCT.

AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024